Author Title Type [ Year(Asc)]
Filters: Author is Hashmi, Shahrukh K  [Clear All Filters]
Mohammed, J., Aljurf, M., Althumayri, A., Almansour, M., Alghamdi, A., Hamidieh, A.Ali, Elhaddad, A., Ben Othman, T., Bazarbachi, A., Almohareb, F., et al. (2019). Physical therapy pathway and protocol for patients undergoing hematopoietic stem cell transplantation: Recommendations from The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group.Hematol Oncol Stem Cell Ther.
Mohammed, J., Smith, S.R., Burns, L., Basak, G., Aljurf, M., SavaniMD, B.N., Schoemans, H., Peric, Z., Chaudhri, N.A., Chigbo, N., et al. (2019). Role of physical therapy pre and post hematopoietic stem cell transplantation - White paper report.Biol Blood Marrow Transplant.
Hickson, L.T.J., Prata, L.G.P.Langhi, Bobart, S.A., Evans, T.K., Giorgadze, N., Hashmi, S.K., Herrmann, S.M., Jensen, M.D., Jia, Q., Jordan, K.L., et al. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.Ebiomedicine.
Hashmi, S.K. (2019). The strange case of Dr. Hashmi and Mr. Hyde.Hematol Oncol Stem Cell Ther.
Pasquini, M.C., Srivastava, A., Ahmed, S.Osman, Aljurf, M., Atsuta, Y., Doleysh, C., Galeano, S., Gluckman, E., Greinix, H., Hale, G., et al. (2019). Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond.Hematol Oncol Stem Cell Ther.
Hunjan, M.K., Nowsheen, S., Rodriguez, A.J., Hashmi, S.K., Bridges, A.G., Lehman, J.S., and El-Azhary, R. (2018). Clinical and histopathological spectrum of toxic erythema of chemotherapy in patients who have undergone allogenic hematopoietic cell transplantation.Hematol Oncol Stem Cell Ther.
Kansagra, A.J., Frey, N.V., Bar, M., Laetsch, T.W., Carpenter, P.A., Savani, B.N., Heslop, H.E., Bollard, C.M., Komanduri, K.V., Gastineau, D.A., et al. (2018). Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl.Biol Blood Marrow Transplant.
Chhabra, S., Liu, Y., Hemmer, M.T., Costa, L., Pidala, J.A., Couriel, D.R., Alousi, A.M., Majhail, N.S., Stuart, R.K., Kim, D., et al. (2018). Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation.Biol Blood Marrow Transplant.
Torres, M.E., Hashmi, S.K., Stevens, M.A., Tan, A.D., Callahan, V., Sloan, J.A., Hogan, W.J., Litzow, M.R., Roy, V., Foran, J.M., et al. (2018). Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant.Hematol Oncol Stem Cell Ther.
Alousi, A., Wang, T., Hemmer, M.T., Spellman, S.R., Arora, M., Couriel, D.R., Pidala, J., Anderlini, P.N., Boyiadzis, M., Bredeson, C.N., et al. (2018). Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival.Biol Blood Marrow Transplant.
Radivoyevitch, T., Dean, R.M., Shaw, B.E., Brazauskas, R., Tecca, H.R., Molenaar, R.J., Battiwalla, M., Savani, B.N., Flowers, M.E.D., Cooke, K.R., et al. (2018). Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.Leuk Res.